A human therapeutic that specifically modulates skeletal muscle growth would potentially provide a benefit for a variety of conditions including sarcopenia, cachexia, and muscular dystrophy. Myostatin, a member of the TGF-beta family of growth factors, is a known negative regulator of muscle mass, as mice lacking the myostatin gene have increased muscle mass. Thus, an inhibitor of myostatin may...

Myostatin is an important negative regulator of muscle growth. Natural mutations and knockouts in animals produce a “double-muscled” phenotype the basis of which is a dramatic increase in muscle mass. Therapeutics that target myostatin are currently in development. There are almost no documented side effects of suppression, and early research suggests that myostatin inhibition can restore funct...

BACKGROUND Cardiac cachexia is characterized by an exaggerated loss of skeletal muscle, weakness, and exercise intolerance, although the cause of these effects remains unknown. Here, we hypothesized that the heart functions as an endocrine organ in promoting systemic cachexia by secreting peptide factors such as myostatin. Myostatin is a cytokine of the transforming growth factor-beta superfami...

Abstract Myostatin is a negative regulator of muscle mass and its inhibition represents promising strategy for the treatment disorders type 2 diabetes. However, there currently no clinically effective myostatin inhibitor, therefore novel methods are required. We evaluated use antisense phosphorodiamidate morpholino oligomers (PMO) to reduce expression in skeletal measured their effects on gluco...

Background and Objectives: Muscular atrophy is one of the indicators of uncontrolled diabetes. The aim of the current study was to investigate effects of eight weeks of resistance training (RT) on myostatin gene expression in soleus muscles and insulin resistance in streptozotocin (STZ)-induced diabetic rats. Materials and Methods: In general, 14 Wistar male rats weighing 200–250 g and aging 8...

MicroRNAs are endogenous ~22nt RNAs that negatively regulate gene expression at the posttranscriptional level via binding to the 3'-untranslated region (3'UTR) of target mRNAs. The microRNA miR-27a was reported to depress the expression of myostatin, a critical inhibitor of skeletal myogenesis, by binding to its 3'UTR in mouse. In this study, we cloned the full-length 3'UTR of porcine myostatin...

Myostatin, which is a member of the TGF-beta superfamily, is a negative regulator of skeletal muscle formation. Double-muscled Piedmontese cattle have a C313Y mutation in myostatin and show increased skeletal muscle mass which resulted from an increase of myofiber number (hyperplasia) without that of myofiber size (hypertrophy). To examine whether this mutation in myostatin gene affects muscle ...

Myostatin is a novel negative regulator of skeletal muscle mass. Myostatin expression is also found in heart in a much less extent, but it can be upregulated in pathological conditions, such as heart failure. Myostatin may be involved in inhibiting protein synthesis and/or increasing protein degradation in skeletal and cardiac muscles. Herein, we used cell cultures and isolated muscles from rat...

Myostatin is a member of the transforming growth factor beta (TGF-beta) superfamily that functions as a negative regulator of skeletal muscle development and growth. Myostatin blockade therefore offers a strategy for promoting muscle growth in livestock production without resorting to genetic manipulation. In this report, we examined the effect of myostatin inhibition by plasmid-mediated delive...

Mutations in myostatin (GDF8) cause marked increases in muscle mass, suggesting that this transforming growth factor-beta (TGF-beta) superfamily member negatively regulates muscle growth. Myostatin blockade therefore offers a strategy for reversing muscle wasting in Duchenne's muscular dystrophy (DMD) without resorting to genetic manipulation. Here, we demonstrate that pharmacological blockade ...